Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AstraZeneca's revenue for the
three
months ended in Jun. 2026 was €13,353 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was €52,760 Mil.
AstraZeneca's Revenue per Share for the
three
months ended in Jun. 2026 was €4.31.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €16.99.
Warning Sign:
AstraZeneca PLC revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of AstraZeneca was 6.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 6.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 12.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 8.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, AstraZeneca's highest 3-Year average Revenue per Share Growth Rate was 19.90% per year. The lowest was -10.30% per year. And the median was 4.70% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
AstraZeneca Revenue Related Terms
AstraZeneca Revenue Historical Data
* Premium members only.
The historical data trend for AstraZeneca's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, AstraZeneca's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Revenue distribution charts can be found below:
* The bar in red indicates where AstraZeneca's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €52,760 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca (STU:ZEGA) has a Revenue of €52,760 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on AstraZeneca and its competitors.
Is AstraZeneca's Revenue too high?
AstraZeneca's current Revenue is €52,760 Mil. Overall, AstraZeneca has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's Revenue compare to LLY and JNJ?
AstraZeneca's Revenue of €52,760 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on AstraZeneca and its competitors. AstraZeneca's current Revenue is €52,760 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
AstraZeneca (STU:ZEGA) has a current Revenue of €52,760 Mil. The stock's GF Value™ is €86.71, compared to a current price of €78.00 — trading 10% below its estimated fair value. The current Revenue is €52,760 Mil. AstraZeneca's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For AstraZeneca (STU:ZEGA), the current Revenue is €52,760 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca (STU:ZEGA) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued.
The current stock price of €78.00 is trading 10% below its estimated GF Value™ of €86.71.
Key valuation signals for STU:ZEGA:
Revenue: €52,760 Mil
GF Value™: €86.71 vs. price of €78.00 (10% below fair value)
No single metric tells the full story. See the STU:ZEGA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
88GF Score
Get the complete analysis for STU:ZEGA
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ZEGA has been successfully added to your 
